Clinical trial
Combination of Olmesartan and Hydrochlorothiazide in Essential Hypertension
NCT00430950 · Daiichi Sankyo, Industry · Completed
Key facts
| NCT number | NCT00430950 |
|---|---|
| Title | Combination of Olmesartan and Hydrochlorothiazide in Essential Hypertension |
| Official title | Efficacy and Safety of Olmesartan Medoxomil/Hydrochlorothiazide Combination 20/25 mg Versus 40/25 mg in Moderately to Severely Hypertensive Patients Not Adequately Controlled by Olmesartan Medoxomil 40 mg Monotherapy |
| Lead sponsor | Daiichi Sankyo, Industry |
| Collaborators | Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Essential Hypertension |
| Intervention type | Drug |
| Interventions | olmesartan medoxomil (OM)+ hydrochlorothiazide (HCTZ) tablets, olmesartan medoxomil (OM)/ hydrochlorothiazide (HCTZ) 20mg/25mg |
| Enrollment | 1,011 |
| Start date | Feb 1, 2007 |
| Primary completion | May 1, 2008 |
| Completion | Oct 1, 2008 |
| First posted | Feb 2, 2007 |
| Last update posted | Jan 10, 2019 |
| Countries | Belgium, Germany, Netherlands, Slovakia |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: